Compare PTCT & AXTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | AXTA |
|---|---|---|
| Founded | 1998 | 1910 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Paints/Coatings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2006 | 2014 |
| Metric | PTCT | AXTA |
|---|---|---|
| Price | $66.77 | $27.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 14 |
| Target Price | ★ $80.94 | $35.92 |
| AVG Volume (30 Days) | 1.0M | ★ 2.5M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | N/A |
| EPS | ★ 7.78 | 1.74 |
| Revenue | $264,734,000.00 | ★ $5,117,000,000.00 |
| Revenue This Year | N/A | $3.56 |
| Revenue Next Year | $21.65 | $2.93 |
| P/E Ratio | ★ $8.29 | $15.86 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $35.95 | $26.28 |
| 52 Week High | $87.50 | $35.72 |
| Indicator | PTCT | AXTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 21.99 |
| Support Level | $61.43 | $27.43 |
| Resistance Level | $68.44 | $31.01 |
| Average True Range (ATR) | 2.62 | 0.96 |
| MACD | 0.19 | -0.52 |
| Stochastic Oscillator | 55.17 | 6.75 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Axalta Coating Systems Ltd is a manufacturer, marketer, and distributor of high-performance coatings systems. It operates in two segments: Performance Coatings and Mobility Coatings. The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial, and the Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The majority of its revenue is generated from the Mobility Coatings segment. Geographically, the company generates maximum revenue from the Europe, Middle East and Africa (EMEA) region, followed by North America, Asia Pacific, and Latin America.